physulime
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
- Vasopressin V2 receptorANTAGONIST
Vasopressin V2 receptor antagonist
Increased affinity for the V2 over V1a receptor.
Chemistry & pharmacology
Loading structure…
SMILES
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1- Mol. weight
- 427.55 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL420762 ↗
Also known as
- mozavaptan
- mozavaptan
- mozavaptan
- mozavaptan
- mozavaptan
- mozavaptan hcl
- mozavaptan hydrochloride
- opc-31260
- physulime